Last reviewed · How we verify
NCT03309722
Molecular Pathology of Colorectal Cancer: Investigating the Role of Novel Molecular Profiles, microRNA's, and Their Targets in Colorectal Cancer Progression
Status unknown
Last updated 13 October 2017
What this trial tests
trial testing biomarker study in Colorectal Cancer in 1,000 participants. Status unknown.
Timeline
10 October 2008
Primary endpoint
10 October 2020
10 October 2020
10 October 2025
Quick facts
| Lead sponsor | University of Southampton |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 1,000 |
| Start date | 10 October 2008 |
| Primary completion | 10 October 2020 |
| Estimated completion | 10 October 2025 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- biomarker study
Conditions studied
- Colorectal Cancer — all drugs for Colorectal Cancer →
Sponsor
University of Southampton
Who can join
18 and older, any sex, with Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Molecular pathology of Colorectal Cancer: Investigating the role of novel molecular profiles, microRNA's and their targets in Colorectal Cancer progression
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Tumor-derived extracellular vesicles: reliable tools for Cancer diagnosis and clinical applications.
Rahbarghazi R, Jabbari N, Sani NA, Asghari R, et al · · 2019 · cited 160× · PMID 31291956 · DOI 10.1186/s12964-019-0390-y -
Exosomal microRNAs derived from colorectal cancer-associated fibroblasts: role in driving cancer progression.
Bhome R, Goh RW, Bullock MD, Pillar N, et al · · 2017 · cited 114× · PMID 29283887 · DOI 10.18632/aging.101355 -
The Impact of miRNA in Colorectal Cancer Progression and Its Liver Metastases.
Balacescu O, Sur D, Cainap C, Visan S, et al · · 2018 · cited 110× · PMID 30469518 · DOI 10.3390/ijms19123711 -
microRNA-based diagnostic and therapeutic applications in cancer medicine.
Sempere LF, Azmi AS, Moore A. · · 2021 · cited 97× · PMID 33998154 · DOI 10.1002/wrna.1662 -
Targeting miRNAs and Other Non-Coding RNAs as a Therapeutic Approach: An Update.
Bayraktar E, Bayraktar R, Oztatlici H, Lopez-Berestein G, et al · · 2023 · cited 51× · PMID 37104009 · DOI 10.3390/ncrna9020027 -
The ZEB2-dependent EMT transcriptional programme drives therapy resistance by activating nucleotide excision repair genes ERCC1 and ERCC4 in colorectal cancer.
Sreekumar R, Al-Saihati H, Emaduddin M, Moutasim K, et al · · 2021 · cited 36× · PMID 33931939 · DOI 10.1002/1878-0261.12965 -
Stage-specific treatment of colorectal cancer: A microRNA-nanocomposite approach.
Fadaka AO, Akinsoji T, Klein A, Madiehe AM, et al · · 2023 · cited 17× · PMID 38174117 · DOI 10.1016/j.jpha.2023.07.008 -
What Is Known about Theragnostic Strategies in Colorectal Cancer.
Parisi A, Porzio G, Pulcini F, Cannita K, et al · · 2021 · cited 13× · PMID 33535557 · DOI 10.3390/biomedicines9020140
Verify or expand the search:
- PubMed search for NCT03309722
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of biomarker study
Trials testing the same drug.
- NCT03195192 — Utilizing Multiomic Advanced Diagnostics to Identify CDK 4/6 Inhibitor Response Predictors and a Post-treatment Multiomi · NA · completed
Other recruiting trials for Colorectal Cancer
Currently open trials in the same condition.
- NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
- NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
- NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
- NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
- NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting
Other University of Southampton trials
Trials by the same sponsor.
- NCT07531277 — Developing Resource Interventions for Healthcare Professionals and Patients to Improve Knowledge About Fertility in Prim · NA · not yet recruiting
- NCT06923943 — Predicting Nurse Staffing Requirements From Routinely Collected Data · active not recruiting
- NCT06692959 — A Phase II Trial of Neoadjuvant PD-1 Vaccine PD1-Vaxx in Operable MSI High Colorectal Cancer · Phase 2 · recruiting
- NCT06815120 — A Novel Ureteric Stent in Kidney Stone Patients and Oncology Patients Compared to a Conventional JJ Stent · NA · not yet recruiting
- NCT06566157 — PROMOTE: The Effect of a Six Week Prebiotic Supplementation on Wellbeing of Young Adults. · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT03309722 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Southampton
- Last refreshed: 13 October 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03309722.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing